DCA
AZN icon

DSG Capital Advisors’s AstraZeneca AZN Stock Holding History

DSG Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$231K Sell
1,172
-28
-2% -$5.4K 0.04% 120
2025
Q4 		$226K Buy
+1,200
New +$210K 0.03% 114

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

DSG Capital Advisors's AZN Position: Q1 2026 in Review

DSG Capital Advisors reduced its AstraZeneca (AZN) stake by 2.3% in Q1 2026, selling an estimated $5.4K and leaving 1,172 shares worth $231K. The position accounts for 0.04% of the portfolio, ranked #120.

DSG Capital Advisors first reported a position in AZN in Q4 2025 and has held it in 2 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • DSG Capital Advisors held 1,172 shares of AstraZeneca worth $231K as of Q1 2026.
  • DSG Capital Advisors sold 28 AstraZeneca shares in Q1 2026, an estimated $5.4K.
  • AstraZeneca made up 0.04% of DSG Capital Advisors's portfolio in Q1 2026, its #120 holding.
  • DSG Capital Advisors first reported a position in AstraZeneca in Q4 2025 and has held it in 2 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on DSG Capital Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.